Metagenomic Sequencing of Sputum DNA Shows Potential for Future Tuberculosis Dx

The Personalized Medicine Coalition announced that Daryl Pritchard will be its new VP of science policy, in charge of promoting the organization's science-related policies and of raising awareness of precision healthcare issues among policymakers, providers, and patients. Before joining PMC, Pritchard was director of policy research at the National Pharmaceutical Council; director of research programs advocacy and personalized medicine at the Biotechnology Industry Organization; and the director of government affairs for the American Association for Dental Research.

Nabsys has appointed Steve Lombardi to president, CEO, and to its board of directors. Previously, he was CEO of Real Time Genomics, and before that he was CEO of Helicos BioSciences. He has also served as senior vice president of Affymetrix and vice president of genetic analysis at Applied Biosystems.

Roche said this week that Arthur Levinson has resigned from its board of directors, effective immediately. The drugmaker said Levinson, who was chairman and CEO at Genentech from 1999 to 2014, made the decision to avoid any conflict with his post as CEO at Calico, a Google-backed startup. Levinson has served on Roche's board since 2010.

Sanford Burnham Medical Research Institute said this week it has named Perry Nisen as its CEO and as holder of the Donald Bren Chief Executive Chair. Nisen joins Sanford Burnham from GlaxoSmithKline, where he was senior VP of science and innovation.

The New York Genome Center has named Carol Ashe its new chief business officer. She previously served as VP of corporate development for pharmaceutical firm Endo International, and prior to that was a partner at GlaxoSmithKline's venture capital fund, SR One. Ashe also led GSK's US corporate legal group, which supported M&A transactions and the business development legal transactions team.

Continued here:
Metagenomic Sequencing of Sputum DNA Shows Potential for Future Tuberculosis Dx